Androgen activity in the normal male embryonic hindbrain drives lethal PFA ependymoma
Androgen activity in the normal male embryonic hindbrain drives lethal PFA ependymoma
Dr. Jiao Zhang, Ph.D. – Baylor College of Medicine, Houston TX
Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy
Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy
Dr. Ketan Ghaghada, Ph.D. – Baylor College of Medicine, Houston TX
Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma
Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma
Dr. Jamie Anastas, Ph.D. – Baylor College of Medicine, Houston, TX
CAR gamma delta T cell-based multi-pronged immunotherapy for AML
CAR gamma delta T cell-based multi-pronged immunotherapy for AML
Dr. Norihiro Watanabe, Ph.D. – Baylor College of Medicine
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dr. Palaniraja Thandapani, Ph.D. – University of Texas M.D. Anderson Cancer Center, Houston, TX
A PHASE 1 STUDY OF REVUMENIB, AZACITIDINE, AND VENETOCLAX AND IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
A PHASE 1 STUDY OF REVUMENIB, AZACITIDINE, AND VENETOCLAX AND IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
Dr. Hiroto Inaba, M.D. – St. Jude Children's Research Hospital, Inc., Memphis, TN
Targeting RNA Condensates in Pediatric Myeloid Leukemia
Targeting RNA Condensates in Pediatric Myeloid Leukemia
Dr. Bruno Di Stefano, Ph.D. – Baylor College of Medicine, Houston, TX
Discovery of novel MDM2-targeted therapy for pediatric AML
Discovery of novel MDM2-targeted therapy for pediatric AML
Dr. Muxiang Zhou – Emory University, Atlanta, GA
Targeting the IKAROS-SAMHD1 axis in KMT2A rearranged B-ALL
Targeting the IKAROS-SAMHD1 axis in KMT2A rearranged B-ALL
Baylor College of Medicine, Houston, TX
Optimizing Pediatric Cancer Immunotherapy with Nano-Targeted Off-the-Shelf Natural Killer T Cells
Optimizing Pediatric Cancer Immunotherapy with Nano-Targeted Off-the-Shelf Natural Killer T Cells
University of Miami, Miami, FL
Targeting ATR/SPOP Signaling to Overcome Chemotherapy Resistance in Ewing Sarcoma
Targeting ATR/SPOP Signaling to Overcome Chemotherapy Resistance in Ewing Sarcoma
The University of North Carolina at Chapel Hill, Chapel Hill, NC
Enhancement of Oncolytic Virotherapy with Directed Drug Delivery for Pediatric Brain Tumors
Enhancement of Oncolytic Virotherapy with Directed Drug Delivery for Pediatric Brain Tumors
MD Anderson Cancer Center, Houston, TX
Boosting Immunovirotherapy with Tumor Vaccination to Treat Pediatric Malignant Brain Tumors
Boosting Immunovirotherapy with Tumor Vaccination to Treat Pediatric Malignant Brain Tumors
University of Alabama at Birmingham, Birmingham, AL
Uncovering the Contribution of RNA Binding Proteins to Neuroblastoma Aggression
Uncovering the Contribution of RNA Binding Proteins to Neuroblastoma Aggression
Emory University – Winship Cancer Institute, Atlanta, GA
A Novel Approach to Target ACVR1 as a Treatment to Pediatric Cancer
A Novel Approach to Target ACVR1 as a Treatment to Pediatric Cancer
Georgia Tech Research Corporation, Atlanta, GA
Targeting RNA Processing Defects of Ewing Sarcoma
Targeting RNA Processing Defects of Ewing Sarcoma
UT Health Science Center at San Antonio, San Antonio, TX
Developing A Novel Therapeutic Strategy for Rhabdomyosarcoma
Developing A Novel Therapeutic Strategy for Rhabdomyosarcoma
UT Southwestern Medical Center, Dallas, TX
Targeting Signaling Pathways that Confer Cytarabine Resistance in Pediatric AML
Targeting Signaling Pathways that Confer Cytarabine Resistance in Pediatric AML
Baylor College of Medicine, Houston, TX
Targeting Beta-Catenin Mediated Activity in Metastatic Osteosarcoma
Targeting Beta-Catenin Mediated Activity in Metastatic Osteosarcoma
Baylor College of Medicine, Houston, TX
Phase I Polio Oncolytic Virotherapy (PVS-RIPO) of Pediatric High-Grade Glioma
Phase I Polio Oncolytic Virotherapy (PVS-RIPO) of Pediatric High-Grade Glioma
Duke University Medical Center, Durham, NC